Mitochondrial Dysfunction and Bioenergetics in Chronic Obstructive Pulmonary Disease: Mechanisms, Biomarkers, and Therapeutic Opportunities
The Yale Journal of Biology and Medicine · 2026-11-04 · 99 (3) · 547-557
DOI: 10.59249/uvmv3274 ↗At a glance
Übersichtsarbeit in The Yale Journal of Biology and Medicine, published online on 2026-11-04. Written by Rishit Bhat and 7 co-authors. Institution: Molecular, Cell, and Developmental Biology University of California, Los Angeles. Major MEDLINE topics: Pulmonary Disease, Chronic Obstructive, Mitochondria, Biomarkers, Energy Metabolism. The full text is freely available in PubMed Central.
Topics: COPD
Abstract (original language)
Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by chronic respiratory symptoms and persistent obstruction of airflow arising from abnormalities of the airways and/or alveoli. Its pathogenesis includes multiple interacting exposures and susceptibilities, including cigarette smoking, biomass and occupational exposures, air pollution, and genetic factors. Per this paradigm, researchers have historically focused on developing broad anti-inflammatory therapeutics that manage acute symptoms but fail to arrest progressive decline. Within this heterogeneous disease framework, mitochondrial dysfunction may contribute to chronic obstructive pulmonary disease pathobiology through interactions with oxidative stress, inflammation, impaired quality control, and altered cellular bioenergetics. We evaluate mitochondrial-associated biomarkers for disease severity, progression, and patient stratification, while considering their limited specificity and susceptibility to confounding by aging and comorbidities. We also assess the limitations of broad-spectrum antioxidant strategies and examine mitochondrial-targeted antioxidants and metabolic modulators, such as SS-31, MitoQ, and metformin. In addition, the review examines emerging mitochondrial stress pathways, including OMA1-DELE1-HRI signaling, while emphasizing that their direct involvement in chronic obstructive pulmonary disease remains unestablished. Altogether, the evidence available supports mitochondrial biology as a complementary area of investigation within the broader inflammatory, structural, and metabolic heterogeneity of chronic obstructive pulmonary disease, while our review reveals that substantial mechanistic and clinical validation remains necessary.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Molecular, Cell, and Developmental Biology University of California, Los Angeles.
- Computational and Systems Biology University of California, Los Angeles.
- Mathematics University of California, Los Angeles.
- Integrative Biology and Physiology University of California, Los Angeles.
- Physiology and Medical Sciences University of Arizona, Tucson.
- Psychology University of California, Los Angeles.
ORCID profiles: Rishit Bhat, Zaid Vellani
Cite
APA
Bhat, R., Dunne, L. B., Miles, S., Kazi, A., Siddiqui, D., Warriach, M. N., Ofoegbu, C. T., & Vellani, Z. (2026). Mitochondrial Dysfunction and Bioenergetics in Chronic Obstructive Pulmonary Disease: Mechanisms, Biomarkers, and Therapeutic Opportunities. The Yale Journal of Biology and Medicine, 99(3), 547-557. https://doi.org/10.59249/uvmv3274
Vancouver
Bhat R, Dunne LB, Miles S, Kazi A, Siddiqui D, Warriach MN, et al. Mitochondrial Dysfunction and Bioenergetics in Chronic Obstructive Pulmonary Disease: Mechanisms, Biomarkers, and Therapeutic Opportunities. The Yale Journal of Biology and Medicine. 2026;99(3):547-557. doi:10.59249/uvmv3274
BibTeX
@article{Bhat2026,
author = {Bhat, Rishit and Dunne, Liam B and Miles, Sophia and Kazi, Ahmad and Siddiqui, Daniyal and Warriach, Mutahhar N and Ofoegbu, Chibudom T and Vellani, Zaid},
title = {Mitochondrial Dysfunction and Bioenergetics in Chronic Obstructive Pulmonary Disease: Mechanisms, Biomarkers, and Therapeutic Opportunities},
journal = {The Yale Journal of Biology and Medicine},
year = {2026},
volume = {99},
number = {3},
pages = {547--557},
doi = {10.59249/uvmv3274}
}
EUVIMED